In addition, hospitalizations for HF (HR 0·69; 95% CI 0·62–0·76; p<0·0001; I2=0%; Fig. 3) and urgent visits for HF (OR 0·39; 95% CI 0·22–0·69; p = 0·001; I2=0%; Supplementary Figure 1) were significantly reduced in those receiving SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and hydrops fetalis.